NASDAQ:VYGR Voyager Therapeutics Q2 2025 Earnings Results & Report $1.76 -0.07 (-3.84%) As of 03:49 PM Eastern This is a fair market value price provided by Massive. Learn more. Voyager Therapeutics missed analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of -$0.57 versus the -$0.48 consensus estimate, while revenue of $5.20 million fell short of the $9.50 million estimate by $4.30 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 6, 2025TimeBefore Market OpensConference Call4:00 PM ET Voyager Therapeutics EPS ResultsActual EPS-$0.57Consensus EPS -$0.48Beat/MissMissed by -$0.09One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersVoyager Therapeutics Revenue ResultsActual Revenue$5.20 millionExpected Revenue$9.50 millionBeat/MissMissed by -$4.30 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Voyager Therapeutics Q2 2025 Earnings FAQ Did Voyager Therapeutics beat earnings estimates for Q2 2025? Voyager Therapeutics (NASDAQ:VYGR) reported earnings of -$0.57 per share for Q2 2025, missing the consensus estimate of -$0.48. The report was announced on Wednesday, August 6, 2025. What was Voyager Therapeutics' revenue for Q2 2025? Voyager Therapeutics reported revenue of $5.20 million for Q2 2025, against a consensus estimate of $9.50 million. Voyager Therapeutics Earnings HeadlinesVoyager Therapeutics (NASDAQ:VYGR) Downgraded by Wall Street Zen to Strong SellNovember 7, 2026 | americanbankingnews.comVoyager Reports Third Quarter 2026 Financial and Operating ResultsNovember 6, 2026 | markets.businessinsider.comGOP wipeout … but here's WORSE news for the marketA 3 trillion dollar crisis may be building beneath the surface of the stock market, retirement accounts, pensions, and even banks. Reuters reports alarm bells echoing 2007 subprime warnings, and bestselling author Dr. Martin Weiss says this one may already be underway. His free briefing outlines five steps investors are considering to help protect their portfolios.November 11 at 1:00 AM | Weiss Ratings (Ad)Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026October 27, 2026 | markets.businessinsider.comVoyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026October 27, 2026 | globenewswire.comVoyager Therapeutics (VYGR) Gets a Buy from Wells FargoOctober 24, 2026 | theglobeandmail.comSee More Voyager Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Voyager Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Voyager Therapeutics and other key companies, straight to your email. Email Address About Voyager TherapeuticsVoyager Therapeutics (NASDAQ:VYGR) is a biotechnology company focused on developing gene therapies for neurological diseases. The company aims to address conditions affecting the central nervous system by using adeno-associated virus (AAV) gene-delivery technologies to deliver therapeutic genes to targeted areas of the brain and nervous system. Voyager’s research platform, known as TRACER, is designed to identify AAV capsids with improved ability to cross the blood-brain barrier and reach the central nervous system. Its development programs have included investigational therapies for diseases such as Alzheimer’s disease, Huntington’s disease and Friedreich’s ataxia. The company has also pursued approaches intended to reduce or modify disease-causing proteins, including tau and mutant huntingtin. Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager has entered strategic collaborations and licensing arrangements with larger biopharmaceutical companies, including Novartis, to support the development and commercialization of certain gene-therapy programs and delivery technologies. The company’s leadership has included Alfred Sandrock Jr., M.D., Ph.D., as chief executive officer.View Voyager Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Can Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandThe Trade Desk Beats on Revenue, But the Fine Print MattersWhy Kinder Morgan's Chairman Just Bought $15 Million in StockA $4 Billion Jolt: NRG Energy Powers Data Center Ambitions Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
